Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Transcript
You are presenting data on the adverse events associated with teprotumumab. What did you find?
I think this is an extremely important question, especially since it concerns patient safety. Now, if you look at the original trials, the most common side effects related to headaches, fatigue, muscle cramps. And these were easily dealt with adequate hydration and rest. And on the other side of the spectrum, they also found that patients with diabetes had a propensity to increase the glucose levels once they've been treated with teprotumumab. Now, once again, with careful monitoring a lot of the serious sort of outcomes of this are circumvented and in my experience, good management of these patients means that the glucose levels, even if they do spike, are easily caught and managed on the spot.
Now, one of the other adverse events that seems to be interesting is disturbances in hearing there have been a few patients that have experienced tinnitus following treatment with teprotumumab. And at this stage, most conditions have been found to be reversible. There have been a few instances where patients have had more long-term hearing disturbance, but it remains unclear if they had hearing disturbances to begin with before treatment. So, to look into this in more detail, we've designed some studies that will prospectively look at hearing disturbance to try and see the full incidence and prevalence in patients treated with teprotumumab.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More